Novartis AG
SWXNovartis heads into the final stretch of Q3 with a 7% monthly pullback, a clean borrow market, and Q4 earnings on the horizon — the tension is whether the stock's defensive credentials can hold while momentum softens. The price action this month tells a clear story of pressure followed by partial recovery. NOVN closed at CHF 113.84 on September 15, down 7% from a month ago, though…
NOVN cost to borrow soars 187% in one week to 1.96%, driven by tightening lending conditions on the Swiss pharma giant.
A new long-form analysis for NOVN this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumNovartis heads into the final stretch of Q3 with a 7% monthly pullback, a clean borrow market, and Q4 earnings on the horizon — the tension is whether the stock's defensive credentials can hold while momentum…
Snapshot as of 20 Sept 2026
NOVN enters the first week of September in a comfortable position — up nearly 5% on the week to CHF 129.58, outrunning most of its large-cap pharma peers while short sellers show little appetite to press the other…
NOVN heads into the back half of August in a quietly unusual position: the stock is up on the week while most of its closest peers are not, short sellers have almost no presence, and the analyst community sees…
NOVN enters the final stretch before its July 21 Q2 results on a quiet but genuinely divergent note — up 3.1% on the week while most of its closest peers are in the red. The outperformance stands out against a mixed…
Novartis heads into the second week of June down 4.6% on the week, closing at CHF 113.00 — yet today's news flow is pulling hard in the other direction. The week's sharpest tension is the gap between a softening share…
NOVN enters the week down 8% over the past month, closing Tuesday at CHF 113.54. The most striking tension here is the gap between insider behaviour — persistent and sizeable selling — and an analyst community that…
NOVN arrives at its Q1 2026 results today with one of the most striking setup features being the near-complete retreat of short sellers over the past six weeks. Short interest has collapsed. The SI % of free float has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NOVN — free to start on ORTEX.
Sign up for free →Open NOVN on ORTEX